Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial

BACKGROUND: Administration of Janus kinase (JAK) inhibitors and biological disease-modifying antirheumatic drugs has dramatically improved even the clinical outcomes in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX). Dysregulation of JAK-STAT pathways via ov...

Descripción completa

Detalles Bibliográficos

Autores principales:	Shimizu, Toshimasa, Kawashiri, Shin-ya, Morimoto, Shimpei, Kawazoe, Yurika, Kuroda, Shohei, Kawasaki, Rina, Ito, Yasuko, Kiya, Rieko, Sato, Shuntaro, Yamamoto, Hiroshi, Kawakami, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985291/ https://www.ncbi.nlm.nih.gov/pubmed/36869356 http://dx.doi.org/10.1186/s13063-023-07176-5